Aims-To describe the prostatic adenectomy specimens of six patients with symptomatic benign prostatic hyperplasia (BPH) who failed to respond to long term treatment with a 5-a-reductase inhibitor, finasteride. Methods-Histological sections from six cases of BPH who had been treated with finasteride were investigated. Five patients were prescribed 5 mg finasteride daily for six months and one patient 5 mg daily for 12 months. The patients underwent adenectomy as their urethral obstruction failed to resolve. Twenty cases ofuntreated BPH served as controls. Results-In patients taking finasteride for six months the prostatic adenectomy specimens showed a reduction in the size of the prostate and an increase in the stroma:epithelial and stroma:lumen ratios .compared with controls. The size of the ducts and acini was not as uniform as in the controls. In particular, some ducts and acini were still lined by a bistratified epithelium similar to that found in controls but lacked undulations at the epithelial border; other ducts/acini were atrophic. Some scattered clusters ofsmall acini with a focally fragmented basal cell layer were observed in two of the five treated cases. One prostatic adenectomy specimen, from the patient treated for one year, showed extensive lobular atrophy and diffuse squamous and transitional cell metaplasia. At the periphery of the transition zone, there was a complex intra-acinar papillary-cribriform proliferation of clear cells without nuclear atypia, similar to clear cell papillary hyperplasia. The periurethral region showed stromal nodules in both patients and controls. Conclusions-Morphological evaluation offinasteride treated BPH showed changes in the lobules of the transition zone, but not in the periurethral stroma.
Benign prostatic hyperplasia (BPH) arises within the transition zone of the prostate, including the periurethral region.' Most of the periurethral nodules are pure stromal nodules, reminiscent of embryonic mesenchyme. In the transition zone, however, almost all of the nodules are glandular from their inception. The hyperplastic glands differ from the surrounding transition zone tissue only in their architectural arrangement. Nodules arise by the budding of new small glands from pre-existing ducts and acini. ' The resulting enlargement of the prostate gland often leads to urethral obstruction and even complete urinary retention. 23 Androgens are required to maintain the size and function of the prostate.245 The androgen primarily responsible for prostatic growth and enlargement is dihydrotestosterone (DHT).2 DHT, converted from testosterone by the enzyme 5-a-reductase, is also thought to be the major factor in the development of BPH. Selective inhibition of 5-a-reductase is considered to be an effective treatment for BPH, without causing severe androgen deficiency effects in other tissues.3 Some reports have proposed that the administration of a competitive inhibitor of 5-oc-reductase, such as finasteride, can cause a decrease in the size of the prostate by an order of magnitude similar to that seen in androgen ablation with luteinising hormone-releasing hormone analogs or flutamide administration, or both.67 In fact, a significant decrease in the symptoms of obstruction, including increased urinary flow, and in prostatic volume has been observed in many patients. 6 The effects of finasteride are thought to be the result of involution of the prostatic epithelium,6 7 
Results

FINASTERIDE TREATMENT FOR SIX MONTHS
On examination of prostatic adenectomy specimens from treated patients, the size of the prostate was reduced compared with controls (untreated BPH samples). In particular, considering the transverse diameter of the specimens (that is, width from left lateral to right lateral side), the values recorded in the untreated patients were always >6 cm. By contrast, the lengths in the treated patients were between 4 and 6 cm.
The untreated group showed ducts and acini of relatively uniform size ( fig 1) . In the treated group there was an increase in the stroma: epithelial and the stroma:lumen ratios-for example, in the untreated group, the stroma: epithelial and the stroma:lumen ratios, judged visually, were 5:1 and 3:1, respectively; in the treated group, the stroma:lumen and stroma: epithelial ratios were 7-10:1, because of a reduction in the epithelial and lumen components, whereas the size of the ducts and acini was not as uniform as in untreated BPH. In fact, some ducts and acini in the treated group were still lined by a bistratified epithelium similar to that of untreated BPH but lacked un- dulations at the epithelial border; other ducts/ acini were atrophic (fig 2) . In the treated group, the secretory cells had inconspicuous nucleoli and nuclear shrinkage together with some chromatin condensation. Some apoptotic bodies" were present between the epithelial cells as well as in the lumens; no mitotic figures were seen. A degree of secretory cell cytoplasmic clearing and also basal cell layer prominence were present after the treatment with finasteride. Focal squamous and transitional cell metaplasia was seen mainly in the periurethral region in the treated group. Budding of some small glands from preexisting ducts and acini (fig 3) was rarely seen in untreated BPH.' Some scattered clusters of small acini with a mixture of round, regular and irregular contours were observed in two cases of the finasteride treated group (fig 4) . Adjacent acini invariably showed typical atrophic changes. In these small acini the secretory a . 'X4 t r'''. atrophy".
It is generally accepted that finasteride blocks 5-oa-reductase, thereby reducing hormonal stimulation of the epithelial prostate component. 3 In fact, the lack of mitotic figures in the ducts and acini indicates that there is no growth of the epithelial component as a result of this treatment. This is in agreement with a recent study published by Bologna et all4 who assessed the effects of finasteride on the growth rate of the LnCap human prostate carcinoma cell line. They found that the growth rate of this cell line could be inhibited by the inhibition of 5-oa-reductase. The question one might ask is whether the epithelial atrophy is the result ofa lack ofstimulation or the result ofactivation of other involution mechanisms. As apoptotic bodies were present in our specimens, apoptosis was probably triggered by finasteride. '5 This phenomenon has already been observed and described in normal, preinvasive and invasive human prostate lesions after total androgen ablation. 1 -l3 Tuttle et all6 investigated the effect of 5-ca-reductase inhibition on the growth characteristics of the non-androgen dependent human prostate cancer line PC-3. They observed that finasteride caused apoptosis. Lamb et all7 also reported that 5-areductase inhibitors promoted prostatic cell death in rodents. In an experimental study Cohen et al' briefly mentioned a net increase in prostatic cell death in canine BPH. They suggested that greater numbers of cells died after castration than after treatment with inhibitors of 5-oa-reductase.
The finasteride treated group in the present study showed some clusters of small acini morphologically similar to those described in postatrophic hyperplasia of the prostate.'8 Even though it is unclear how these foci are formed, their formation occurs in untreated prostate as a result ofproliferation ofsmall acini originating from atrophic ducts and acini.'5 They are distinguished from carcinoma by their intact or fragmented basal cell layer, inconspicuous or mildly enlarged nucleoli, and adjacent acinar atrophy.
In the specimen from the patient treated with finasteride for 12 months, the ducts and acini had undergone further atrophy and eventually almost disappeared, leaving foci of squamous metaplasia scattered throughout the prostate as a sign of a previous lobule existence. This latter feature is similar to that described by Bainborough'9 following oestrogen therapy. Squamous metaplasia was not a prominent feature in specimens from patients treated for six months, although it was present occasionally.
Changes in the epithelium of some ducts and acini at the periphery of the transition zone were also observed after treatment with finasteride for 12 months. These changes were similar to clear cell papillary hyperplasia-that is, a benign change which could mimic a malignant lesion growing in the duct lumen. Gormley et al6 reported a lack of efficacy in 4% of the men receiving a 5 mg tablet of finasteride daily. They did not comment on the reasons for the lack of success in these men, even though their study concentrated on the evaluation of urinary flow. As our current paper was not based on a double blind, placebo controlled study, we cannot give an exact figure for the lack of clinical improvement in urinary symptoms after long term treatment with finasteride. At our Urology Clinic, finasteride, given to over 100 men with BPH, produced a decrease in obstructive urinary symptoms in most cases. No specimens of successful finasteride treatment were available to us as the patients were not candidates for surgery. In approximately 5% of patients-that is, the six patients whose adenectomy specimens are reported in this study, finasteride did not have any effect. The reason for the lack of clinical efficacy might not be related to the glandular component itself, but could be related to the prostate stroma. For example, nodules ofprimitive mesenchyme were present in the periurethral region after treatment. This could be the result of local variations in 5-ct-reductase expression as well as other factors which might influence the behaviour of the stroma cells, including smooth muscle cells.2'
In conclusion, the morphological evaluation of finasteride treated BPH showed changes in the lobules of the transition zone, but not in the periurethral stroma. 
